DINA 010
Alternative Names: DINA-010Latest Information Update: 28 Mar 2026
At a glance
- Originator DiNAQOR AG
- Class Cardiovascular therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dilated cardiomyopathy; Hypertrophic cardiomyopathy
Most Recent Events
- 28 Mar 2026 No recent reports of development identified for research development in Dilated cardiomyopathy in Switzerland (Parenteral)
- 28 Mar 2026 No recent reports of development identified for research development in Hypertrophic-cardiomyopathy in Switzerland (Parenteral)
- 10 Feb 2022 DiNAQOR AG enters a collaboration with the University Medical Centre Hamburg Eppendorf for testing gene therapies, prior to February 2022